Abiomed, Inc. (ABMD) Income Statement Analysis

See more : Makkah Construction & Development Company (4100.SR) Income Statement Analysis – Financial Results

Complete financial analysis of Abiomed, Inc. (ABMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abiomed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Abiomed, Inc. (ABMD)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.abiomed.com

About Abiomed, Inc.

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987
Revenue	1.03B	847.52M	840.88M	769.43M	593.75M	445.30M	329.54M	230.31M	183.64M	158.12M	126.38M	101.15M	85.71M	73.21M	58.94M	50.65M	43.67M	38.22M	25.74M	23.31M	26.86M	24.90M	22.52M	22.09M	22.45M	16.46M	12.84M	9.20M	6.70M	3.40M	2.70M	2.00M	3.00M	2.90M	4.20M	4.70M
Cost of Revenue	188.16M	161.91M	151.31M	129.57M	98.58M	70.63M	50.42M	39.95M	37.32M	31.60M	24.51M	21.98M	22.53M	20.44M	15.07M	12.01M	11.69M	9.37M	7.59M	7.50M	7.92M	7.38M	5.88M	6.77M	6.50M	5.36M	3.92M	2.90M	1.90M	3.00M	2.00M	1.30M	1.00M	1.10M	200.00K	3.70M
Gross Profit	843.60M	685.62M	689.58M	639.87M	495.17M	374.68M	279.12M	190.37M	146.32M	126.53M	101.87M	79.17M	63.18M	52.77M	43.88M	38.64M	31.99M	28.85M	18.15M	15.81M	18.94M	17.52M	16.64M	15.32M	15.94M	11.10M	8.92M	6.30M	4.80M	400.00K	700.00K	700.00K	2.00M	1.80M	4.00M	1.00M
Gross Profit Ratio	81.76%	80.90%	82.01%	83.16%	83.40%	84.14%	84.70%	82.66%	79.68%	80.02%	80.61%	78.27%	73.72%	72.08%	74.44%	76.28%	73.24%	75.49%	70.51%	67.82%	70.53%	70.38%	73.88%	69.34%	71.03%	67.44%	69.47%	68.48%	71.64%	11.76%	25.93%	35.00%	66.67%	62.07%	95.24%	21.28%
Research & Development	163.40M	121.88M	98.76M	93.50M	75.30M	66.39M	49.76M	35.97M	30.71M	25.65M	27.16M	26.68M	25.95M	25.33M	24.92M	22.29M	30.05M	13.50M	14.30M	20.55M	27.37M	22.67M	15.63M	13.45M	9.09M	3.83M	3.22M	2.50M	2.40M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	321.55M	262.73M	218.15M	164.26M	125.73M	107.25M	84.23M	71.71M	62.29M	60.84M	55.36M	52.66M	42.45M	30.92M	18.61M	14.10M	14.75M	16.20M	12.41M	12.56M	9.77M	9.05M	7.07M	5.74M	4.30M	4.40M	4.60M	6.40M	8.80M	5.20M	4.80M	5.10M	900.00K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	423.49M	334.18M	341.60M	321.55M	262.73M	218.15M	164.26M	125.73M	107.25M	84.23M	71.71M	62.29M	60.84M	55.36M	52.66M	42.45M	30.92M	18.61M	14.10M	14.75M	16.20M	12.41M	12.56M	9.77M	9.05M	7.07M	5.74M	4.30M	4.40M	4.60M	6.40M	8.80M	5.20M	4.80M	5.10M	900.00K
Other Expenses	0.00	51.95M	-4.56M	30.38M	-388.00K	-349.00K	339.00K	-97.00K	49.00K	326.00K	1.48M	1.40M	1.47M	1.61M	2.79M	1.61M	1.31M	13.23M	13.63M	20.37M	0.00	0.00	0.00	0.00	-1.21M	0.00	0.00	400.00K	300.00K	300.00K	600.00K	300.00K	200.00K	200.00K	200.00K	200.00K
Operating Expenses	586.89M	456.06M	440.36M	415.05M	338.03M	284.54M	214.02M	161.70M	137.96M	109.99M	100.35M	90.36M	88.26M	82.29M	80.36M	66.35M	62.28M	32.10M	28.40M	35.30M	43.56M	35.08M	28.20M	23.22M	16.94M	10.90M	8.96M	7.20M	7.10M	4.90M	7.00M	9.10M	5.40M	5.00M	5.30M	1.10M
Cost & Expenses	775.05M	617.97M	591.66M	544.62M	436.61M	355.17M	264.44M	201.65M	175.28M	141.58M	124.86M	112.34M	110.79M	102.73M	95.43M	78.36M	73.96M	41.47M	35.99M	42.80M	51.48M	42.46M	34.08M	29.99M	23.44M	16.26M	12.88M	10.10M	9.00M	7.90M	9.00M	10.40M	6.40M	6.10M	5.50M	4.80M
Interest Income	49.84M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	49.84M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	28.09M	17.38M	8.26M	14.12M	11.01M	6.20M	3.28M	2.77M	2.51M	2.72M	4.34M	3.95M	4.90M	5.02M	6.12M	3.92M	2.74M	1.24M	1.39M	1.70M	1.77M	2.97M	1.69M	1.39M	876.94K	429.61K	349.76K	400.00K	300.00K	300.00K	600.00K	300.00K	200.00K	200.00K	200.00K	200.00K
EBITDA	400.78M	246.94M	257.48M	230.77M	164.45M	94.79M	67.99M	31.24M	10.75M	19.27M	4.83M	-7.56M	-26.90M	-23.18M	-25.24M	-24.10M	-27.55M	-2.12M	-9.04M	-17.96M	-22.85M	-14.59M	-9.88M	-6.52M	-118.18K	629.77K	313.01K	-900.00K	-2.40M	-4.80M	-6.90M	-9.80M	-4.70M	-3.90M	-1.80M	-100.00K
EBITDA Ratio	38.84%	29.14%	30.62%	29.99%	27.70%	21.29%	20.63%	13.56%	5.86%	12.19%	3.82%	-7.47%	-31.38%	-31.66%	-42.82%	-47.58%	-63.09%	-5.56%	-35.11%	-77.05%	-85.08%	-58.62%	-43.86%	-29.51%	-0.53%	3.83%	2.44%	-9.78%	-35.82%	-141.18%	-255.56%	-490.00%	-156.67%	-134.48%	-42.86%	-2.13%
Operating Income	372.69M	229.56M	249.22M	224.81M	157.14M	90.14M	65.10M	28.67M	8.36M	16.54M	1.52M	-11.19M	-25.08M	-29.52M	-36.49M	-28.51M	-30.29M	-3.25M	-10.25M	-19.49M	-24.62M	-17.56M	-11.56M	-7.90M	-995.12K	200.16K	-36.75K	-900.00K	-2.30M	-4.50M	-6.30M	-8.40M	-3.40M	-3.20M	-1.30M	-100.00K
Operating Income Ratio	36.12%	27.09%	29.64%	29.22%	26.47%	20.24%	19.76%	12.45%	4.55%	10.46%	1.20%	-11.06%	-29.26%	-40.32%	-61.90%	-56.29%	-69.36%	-8.51%	-39.83%	-83.62%	-91.67%	-70.54%	-51.34%	-35.78%	-4.43%	1.22%	-0.29%	-9.78%	-34.33%	-132.35%	-233.33%	-420.00%	-113.33%	-110.34%	-30.95%	-2.13%
Total Other Income/Expenses	-182.13M	58.66M	7.61M	38.55M	3.30M	1.21M	734.00K	99.00K	167.00K	319.00K	1.02M	322.00K	6.72M	-1.33M	-3.92M	1.11M	1.20M	911.00K	806.00K	1.32M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	400.00K	400.00K	600.00K	1.20M	1.70M	1.50M	900.00K	700.00K	200.00K
Income Before Tax	190.56M	288.22M	256.83M	263.36M	160.44M	91.34M	65.84M	28.77M	8.53M	16.86M	2.54M	-10.86M	-18.35M	-30.85M	-40.40M	-27.41M	-29.09M	-2.34M	-9.45M	-18.17M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-500.00K	-1.90M	-3.90M	-5.10M	-6.70M	-1.90M	-2.30M	-600.00K	100.00K
Income Before Tax Ratio	18.47%	34.01%	30.54%	34.23%	27.02%	20.51%	19.98%	12.49%	4.64%	10.66%	2.01%	-10.74%	-21.41%	-42.13%	-68.55%	-54.11%	-66.62%	-6.13%	-36.70%	-77.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.43%	-28.36%	-114.71%	-188.89%	-335.00%	-63.33%	-79.31%	-14.29%	2.13%
Income Tax Expense	54.06M	62.70M	53.82M	4.34M	48.27M	39.23M	27.69M	-84.92M	1.18M	1.85M	1.05M	892.00K	671.00K	752.00K	527.00K	475.00K	356.00K	110.00K	172.00K	173.00K	-2.95M	-6.16M	-1.11M	-1.19M	1.51M	-535.10K	-527.87K	-500.00K	400.00K	600.00K	1.20M	1.70M	1.50M	900.00K	700.00K	200.00K
Net Income	136.51M	225.53M	203.01M	259.02M	112.17M	52.12M	38.15M	113.69M	7.35M	15.01M	1.50M	-11.76M	-19.02M	-31.60M	-40.93M	-27.88M	-29.45M	-2.34M	-9.45M	-18.17M	-21.68M	-11.40M	-10.45M	-6.71M	-2.51M	735.26K	491.12K	-400.00K	-2.00M	-3.90M	-5.10M	-6.60M	-1.90M	-2.20M	-600.00K	100.00K
Net Income Ratio	13.23%	26.61%	24.14%	33.66%	18.89%	11.70%	11.58%	49.36%	4.00%	9.50%	1.18%	-11.62%	-22.19%	-43.16%	-69.44%	-55.05%	-67.44%	-6.13%	-36.70%	-77.95%	-80.71%	-45.79%	-46.43%	-30.39%	-11.17%	4.47%	3.82%	-4.35%	-29.85%	-114.71%	-188.89%	-330.00%	-63.33%	-75.86%	-14.29%	2.13%
EPS	3.00	5.00	4.49	5.77	2.54	1.21	0.90	2.80	0.19	0.38	0.04	-0.32	-0.52	-0.91	-1.26	-1.03	-1.15	-0.11	-0.45	-0.87	-1.04	-0.55	-0.59	-0.39	-0.16	0.05	0.04	-0.03	-0.16	-0.30	-0.40	-0.54	-0.18	-0.24	-0.07	0.01
EPS Diluted	2.98	4.94	4.43	5.61	2.45	1.17	0.85	2.65	0.18	0.37	0.04	-0.32	-0.52	-0.91	-1.26	-1.03	-1.15	-0.11	-0.45	-0.87	-1.04	-0.55	-0.59	-0.39	-0.16	0.05	0.04	-0.03	-0.16	-0.30	-0.40	-0.54	-0.18	-0.24	-0.07	0.01
Weighted Avg Shares Out	45.45M	45.14M	45.18M	44.91M	44.15M	43.24M	42.20M	40.63M	39.33M	39.11M	38.37M	37.17M	36.68M	34.88M	32.47M	27.12M	25.65M	21.84M	21.15M	20.99M	20.87M	20.58M	17.58M	17.24M	16.15M	14.32M	13.99M	13.02M	12.50M	13.00M	12.75M	12.22M	10.56M	9.17M	8.57M	6.90M
Weighted Avg Shares Out (Dil)	45.88M	45.67M	45.82M	46.15M	45.85M	44.66M	44.90M	42.86M	41.61M	41.05M	40.17M	37.17M	36.68M	34.88M	32.47M	27.12M	25.65M	21.84M	21.15M	20.99M	20.87M	20.58M	17.58M	17.24M	16.15M	14.32M	13.99M	13.02M	12.50M	13.00M	12.75M	12.22M	10.56M	9.17M	8.57M	6.90M

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

January 12, 2022zacks.com

Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.

Early Feasibility Study Demonstrates Successful Use of Abiomed's preCARDIA Technology

January 12, 2022businesswire.com

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the successful results of the first-in-human early feasibility study of the preCARDIA system.

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

January 10, 2022businesswire.com

DANVERS, Mass.--(BUSINESS WIRE)--Regulators in three countries have granted approvals to Abiomed's Impella surgical products.

Has Abiomed (ABMD) Outpaced Other Medical Stocks This Year?

December 30, 2021zacks.com

Here is how Abiomed (ABMD) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference

December 29, 2021businesswire.com

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 40th annual J.P. Morgan Healthcare Conference.

4 Stocks Growing Earnings Faster Than Sales

December 13, 2021gurufocus.com

Investors may want to consider the following stocks, since they are growing earnings faster than sales, which may indicate efficient operating activities as profit margins expand along with growth.

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

December 6, 2021zacks.com

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes

November 4, 2021businesswire.com

ORLANDO, Fla.--(BUSINESS WIRE)--Two large studies demonstrate complete revascularization with Impella heart pumps improves ejection fraction and long-term patient outcomes.

Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines

November 3, 2021businesswire.com

DANVERS, Mass.--(BUSINESS WIRE)--The 2021 ESC guidelines for treatment of acute heart failure patients elevate technology such as Impella to Class IIa ("should be considered").

TCT 2021 to Highlight Improved Patient Outcomes with Impella's Small, Smart and Connected Technology

November 1, 2021businesswire.com

DANVERS, Mass.--(BUSINESS WIRE)--TCT 2021 showcases data and clinical studies supporting the use of Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure.

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Abiomed, Inc. (ABMD) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories